Congress Wealth Management LLC Neurocrine Biosciences Inc Transaction History

Congress Wealth Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 14, 2023	BUY	$94.11 - $123.02 $165,539 - $216,392	1,759 Added 1.74%	102,698 $10.4 Million
Q4 2022 Feb 02, 2023	SELL	$106.72 - $127.06 $936,361 - $1.11 Million	-8,774 Reduced 8.0%	100,939 $12.1 Million
Q3 2022 Nov 08, 2022	BUY	$92.03 - $107.81 $414,042 - $485,037	4,499 Added 4.28%	109,713 $11.7 Million
Q2 2022 Aug 11, 2022	SELL	$75.79 - $100.07 $31,528 - $41,629	-416 Reduced 0.39%	105,214 $10.3 Million
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $3.46 Million - $4.53 Million	47,798 Added 82.65%	105,630 $9.9 Million
Q4 2021 Feb 04, 2022	BUY	$79.65 - $106.22 $4.61 Million - $6.14 Million	57,832 New	57,832 $4.93 Million

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Congress Wealth Management LLC , based on Form 13F filings with the SEC.

Stay updated on Congress Wealth Management LLC with notifications on news.